Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The prevention of radiocontrast-agent-induced nephropathy by hemofiltration

Article Abstract:

Hemofiltration can substantially reduce the risk of kidney damage in patients with existing kidney disease who must receive contrast agents during any type of diagnostic imaging procedure. Contrast agents are used to create a better diagnostic image, but they can damage the kidneys. Hemofiltration is a type of dialysis that can remove the contrast agent from blood and also dilute the blood in a further effort to protect the kidneys.

Author: Marenzi, Giancarlo, Marana, Ivana, Lauri, Gianfranco, Assanelli, Emilio, Grazi, Marco, Campodonico, Jeness, Trabattoni, Daniela, Fabbiocchi, Franco, Montorsi, Piero, Bartorelli, Antonio L.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Invasive cardiovascular procedures -- optimizing patient safety

Article Abstract:

A type of dialysis called hemofiltration may prevent kidney damage in patients who must receive contrast agents during a diagnostic or therapeutic procedure. Contrast agents are chemicals that are used to make internal organs more visible on X-ray film and displays. However, they are very toxic to the kidneys. Doctors should always use the smallest dosage necessary, especially when treating patients with existing kidney disease.

Author: Hirshfeld, John W., Jr.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
Radiology, Interventional, Interventional radiography

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


N-acetylcysteine and contrast-induced nephropathy in primary angioplasty

Article Abstract:

A study investigates the antioxidant N-acetylcysteine for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty. Results indicate that intravenous and oral N-acetylcysteine may prevent contrast-medium-induced nephropathy with a dose-dependent effect in patients treated with primary angioplasty and may improve hospital outcome.

Author: Veglia, Fabrizio, Marenzi, Giancarlo, Marana, Ivana, Lauri, Gianfranco, Assanelli, Emilio, Grazi, Marco, Campodonico, Jeness, Fabbiocchi, Franco, Montorsi, Piero, Bartorelli, Antonio L., De Metrio, Monica, Galli, Stefano
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
United States, Science & research, Research, Usage, Diagnosis, Risk factors, Heart attack, Acetylcysteine, Angioplasty, IgA glomerulonephritis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Prevention, Complications and side effects, Blood, Kidney diseases, Contrast media, Contrast media (Chemicals), Hemofiltration
Similar abstracts:
  • Abstracts: Ondansetron for the prevention of emesis induced by high-dose cisplatin: a multi-center dose-response study. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
  • Abstracts: Preventing HIV/AIDS among adolescents: schools as agents of behavior change. AIDS risk reduction among a multiethnic sample of urban high school students
  • Abstracts: Mental health problems among adults in tsunami-affected areas in Southern Thailand. Mental Health, Social Functioning, and Attitudes of Kosovar Albanians Following the War in Kosovo
  • Abstracts: Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
  • Abstracts: The effect of amniotic fluid on the human omental artery in vitro. Impairment of growth in fetuses destined to deliver preterm
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.